# Safety and Efficacy Study of Small Interfering Ribonucleic Acid (RNA) Molecule (Cand5) to Treat Wet Age-Related Macular Degeneration

> **NCT00259753** · PHASE2 · COMPLETED · sponsor: **OPKO Health, Inc.** · enrollment: 120 (actual)

## Conditions studied

- Macular Degeneration

## Interventions

- **DRUG:** Bevasiranib

## Key facts

- **NCT ID:** NCT00259753
- **Lead sponsor:** OPKO Health, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-07
- **Primary completion:** 2007-12
- **Final completion:** 2007-12
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2008-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00259753

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00259753, "Safety and Efficacy Study of Small Interfering Ribonucleic Acid (RNA) Molecule (Cand5) to Treat Wet Age-Related Macular Degeneration". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00259753. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*